FMP
CARGO Therapeutics, Inc. Common Stock
CRGX
NASDAQ
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
4.14 USD
0.07 (1.69%)
Latest CRGX News
Stuart Mooney
Jan 30, 2025
Cargo Therapeutics, Inc. (NASDAQ:CRGX) Faces Significant Stock Price Changes and Investor Scrutiny
Cargo Therapeutics, Inc. (NASDAQ:CRGX) is a company involved in the development of innovative therapies. Recently, the company has been under scrutiny due to significant changes in its stock price and investor sentiment. As of January 30, 2025, Truist Financial's analyst Asthika Goonewardene set a price target of $7 for CRGX, while the stock was trading at $13.19. This target suggests a potential decrease of approximately 46.93%. The downgrade from a Buy to a Hold by Truist, as reported by TheF...
The Motley Fool
Aug 16, 2024
Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week
The cancer-focused biotech published its second-quarter results. Its loss was much narrower than analysts had expected.
GlobeNewsWire
May 28, 2024
CARGO Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences.
Zacks Investment Research
May 22, 2024
What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock
CARGO Therapeutics, Inc. (CRGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research
May 22, 2024
Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High?
The consensus price target hints at a 56.3% upside potential for CARGO Therapeutics, Inc. (CRGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MarketBeat
Jan 8, 2024
IPO watch 2024: Which new stocks will hit the market?
Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.
GlobeNewsWire
Jan 3, 2024
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California.
InvestorPlace
Dec 11, 2023
3 New Stock Listings That Can Deliver Multibagger Returns
The U.S. IPO market has been relatively sluggish this year with 149 IPOs. At the same time, disappointing stories outnumbered businesses that created value.
Seeking Alpha
Nov 12, 2023
U.S. IPO Weekly Recap: Reinsurance And CAR T Therapies Lead A 3 IPO Week
Three IPOs and two SPACs debuted this week, while the pipeline got a boost from a flurry of initial filings. Oncology biotech CARGO Therapeutics priced at the bottom of the range to raise $281 million at a $611 million market cap. Reinsurer and specialty insurance provider Hamilton Group priced below the range to raise $225 million at a $1.7 billion market cap.
Market Watch
Nov 10, 2023
Cargo Therapeutics IPO prices at $15 a share, low end of proposed range
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, said late Thursday its initial public offering priced at $15 a share, the low end of its range. The company sold 18.8 million shares to raise $282 million at a valuation of $580.5 million.
